Literature DB >> 22883025

BAFF and BAFF-R levels are associated with risk of long-term kidney graft dysfunction and development of donor-specific antibodies.

A Thibault-Espitia1, Y Foucher, R Danger, T Migone, A Pallier, S Castagnet, C G-Gueguen, A Devys, A C-Gautier, M Giral, J-P Soulillou, S Brouard.   

Abstract

There are lines of evidence that B cells may play a role in transplantation. B cell activating factor, BAFF, is a homotrimer that has been shown to play a role in B cell survival, maturation and activation. To date, little is known of the role of BAFF and its receptors in transplantation. We analyzed the level of BAFF mRNA and its soluble protein, as well as transcripts coding for its receptors, BAFF-R, TACI and BCMA, in the blood of 143 patients with stable kidney transplant function 5 years or more posttransplantation. Three endpoints were analyzed: the time to renal dysfunction, the time to appearance of anti-HLA antibodies and the time to development of donor-specific antibodies. We established threshold values for BAFF and BAFF-R and showed that (1) stable patients with high BAFF-R levels had a higher risk of developing graft dysfunction, (2) patients with lower levels of BAFF transcripts or a higher level of soluble BAFF had a significantly higher risk of developing donor-specific antibodies. These data suggest that BAFF constitutes a risk factor for renal graft dysfunction and development of donor-specific antibodies. They also suggest that agents targeting BAFF-R interactions may offer new therapeutic opportunities in transplantation. © Copyright 2012 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22883025     DOI: 10.1111/j.1600-6143.2012.04194.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  24 in total

Review 1.  B Cells, Antibodies, and More.

Authors:  William Hoffman; Fadi G Lakkis; Geetha Chalasani
Journal:  Clin J Am Soc Nephrol       Date:  2015-12-23       Impact factor: 8.237

2.  B cell modulation in transplantation.

Authors:  M R Clatworthy
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

3.  Transplantation: investigating the role of BAFF in kidney graft dysfunction.

Authors:  Rebecca Kelsey
Journal:  Nat Rev Nephrol       Date:  2012-08-28       Impact factor: 28.314

Review 4.  The Evolving Roles of Memory Immune Cells in Transplantation.

Authors:  Wenhao Chen; Rafik M Ghobrial; Xian C Li
Journal:  Transplantation       Date:  2015-10       Impact factor: 4.939

5.  Human α1-antitrypsin modifies B-lymphocyte responses during allograft transplantation.

Authors:  Mark Mizrahi; Pablo Cal; Martin Rosenthal; David Ochayon; Galit Shahaf; Ziv Kaner; Peter Kachker; Eli C Lewis
Journal:  Immunology       Date:  2013-11       Impact factor: 7.397

6.  B cell activating factor (BAFF) and a proliferation inducing ligand (APRIL) mediate CD40-independent help by memory CD4 T cells.

Authors:  V Gorbacheva; K Ayasoufi; R Fan; W M Baldwin; A Valujskikh
Journal:  Am J Transplant       Date:  2014-12-12       Impact factor: 8.086

7.  Elevated pretransplantation soluble BAFF is associated with an increased risk of acute antibody-mediated rejection.

Authors:  Gemma Banham; Davide Prezzi; Sarah Harford; Craig J Taylor; Rizwan Hamer; Rob Higgins; J Andrew Bradley; Menna R Clatworthy
Journal:  Transplantation       Date:  2013-08-27       Impact factor: 4.939

8.  Impact of donor-specific antibodies on the outcomes of kidney graft: Pathophysiology, clinical, therapy.

Authors:  Maurizio Salvadori; Elisabetta Bertoni
Journal:  World J Transplant       Date:  2014-03-24

9.  Biomarkers in kidney transplantation: From bench to bedside.

Authors:  Natavudh Townamchai; Somchai Eiam-Ong
Journal:  World J Nephrol       Date:  2015-11-06

10.  Serum Soluble B Cell-Activating Factor Is a Non-Invasive Biomarker of Antibody-Mediated Rejection in Kidney Allograft With Satisfactory Risk Stratification Performance But Negligible Diagnostic Value.

Authors:  Shenghui Wu; Xiaojun Su; Qianyu Ye; Yongcheng Wei; Yifang Gao; Mingchuan Huang; Yanxu Chen; Jiali Wang; Qiang Zhang; Qian Fu; Jun Li; Chenglin Wu; Huiting Huang; Bowen Xu; Huanxi Zhang; Longshan Liu; Changxi Wang
Journal:  Front Immunol       Date:  2022-04-13       Impact factor: 8.786

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.